Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 4Terminated 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 358Neoplasms 252Carcinoma, Non-Small-Cell Lung 191Colorectal Neoplasms 174Lung Neoplasms 150Prostatic Neoplasms 148Carcinoma, Hepatocellular 125Leukemia, Myeloid, Acute 94Multiple Myeloma 84Pancreatic Neoplasms 82Neoplasm Metastasis 72Recurrence 67Stomach Neoplasms 66Rectal Neoplasms 65Uterine Cervical Neoplasms 64Ovarian Neoplasms 61Triple Negative Breast Neoplasms 57Squamous Cell Carcinoma of Head and Neck 56Head and Neck Neoplasms 53Glioblastoma 53Brain Neoplasms 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 51Small Cell Lung Carcinoma 48Endometrial Neoplasms 45Melanoma 43Esophageal Neoplasms 42Colonic Neoplasms 42Disease 41Motor Activity 40Lymphoma 40

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Pathologic Processes × 1 year × Clear all
NCT07162883 2025-09-09

Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

Qilu Pharmaceutical Co., Ltd.

Phase 3 Not yet recruiting
122 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Lymphatic Metastasis, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡